IOVA Stock Hits Over 2-Year Highs — Why Iovance Raised Its FY2026 Revenue Outlook

Shares of Iovance Biotherapeutics (IOVA) surged to their highest levels in more than two years on Tuesday, after the biotech firm raised its full-year revenue outlook, citing stronger U.S. demand for its cancer treatments.At the time of writing, IOVA stock was up more than 25% and heading for its f…